Suppliers and packagers for generic pharmaceutical drug: VIMSELTINIB

VIMSELTINIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304	NDA	Deciphera Pharmaceuticals, LLC	73207-302-40	1 CARTON in 1 CARTON (73207-302-40) / 1 BLISTER PACK in 1 CARTON / 8 CAPSULE in 1 BLISTER PACK	2025-02-14
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304	NDA	Deciphera Pharmaceuticals, LLC	73207-302-41	1 CARTON in 1 CARTON (73207-302-41) / 1 BLISTER PACK in 1 CARTON / 4 CAPSULE in 1 BLISTER PACK	2025-02-14
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304	NDA	Deciphera Pharmaceuticals, LLC	73207-303-40	1 CARTON in 1 CARTON (73207-303-40) / 1 BLISTER PACK in 1 CARTON / 8 CAPSULE in 1 BLISTER PACK	2025-02-14

Vimseltinib Supplier Landscape Analysis

Last updated: February 19, 2026

This report details the current landscape of suppliers for vimseltinib, a pharmaceutical drug. It identifies key raw material providers, contract manufacturing organizations (CMOs), and specialized service providers critical for its production and commercialization.

What is Vimseltinib and What is Its Therapeutic Application?

Vimseltinib is a targeted therapy that inhibits the colony-stimulating factor 1 receptor (CSF1R). CSF1R is a receptor tyrosine kinase involved in the regulation of macrophages, monocytes, and osteoclasts. By blocking CSF1R, vimseltinib aims to reduce the number and activity of these cells, which play a role in various inflammatory and autoimmune diseases.

The primary therapeutic application for vimseltinib is in the treatment of tenosynovial giant cell tumor (TGCT). TGCT is a rare, locally aggressive neoplastic condition that arises from the synovium of joints, tendon sheaths, and bursae. It is characterized by the proliferation of neoplastic cells that secrete high levels of colony-stimulating factor 1 (CSF1), leading to an accumulation of CSF1 receptor-bearing macrophages. This accumulation drives tumor growth and inflammation. Vimseltinib's mechanism of action directly addresses this pathway, making it a significant development for patients with this condition.

In December 2023, the U.S. Food and Drug Administration (FDA) approved vimseltinib (brand name Turalio) for the treatment of adult patients with symptomatic TGCT that is unresectable or associated with severe morbidity [1]. This approval marked the first systemic therapy specifically indicated for TGCT and represents a critical step in addressing an unmet medical need.

Key Raw Material Suppliers for Vimseltinib Synthesis

The synthesis of vimseltinib, like any complex small molecule drug, relies on a robust supply chain for specialized chemical intermediates and active pharmaceutical ingredients (APIs). While the precise proprietary synthesis route is confidential to the developer, general knowledge of small molecule API manufacturing allows for the identification of likely critical raw material categories and potential supplier types. These include advanced intermediates, chiral building blocks, and specialized reagents.

Table 1: Potential Critical Raw Material Categories for Vimseltinib

Category	Description	Importance
Advanced Intermediates	Complex organic molecules that are several synthetic steps away from the final API. These often involve multi-step synthesis and purification. For vimseltinib, specific heterocyclic compounds or substituted aromatic rings are probable advanced intermediates.	Their reliable supply is crucial as they represent significant value addition in the synthetic pathway. Delays or quality issues at this stage can severely impact API production timelines and costs.
Chiral Building Blocks	Molecules containing stereocenters that are essential for achieving the specific three-dimensional structure of vimseltinib. Chirality is critical for drug efficacy and safety. The synthesis of chiral molecules often requires specialized reagents or enzymatic processes.	Ensuring enantiomeric purity is paramount. Suppliers capable of high-purity chiral synthesis are vital. Off-spec chiral material can render the entire API batch unusable, necessitating rigorous quality control and robust supplier selection processes.
Specialized Reagents	Catalysts, coupling agents, protecting groups, and other specific chemicals necessary for carrying out particular transformations in the vimseltinib synthesis. This can include organometallic reagents, strong bases, or highly selective oxidants/reductants.	The availability of high-quality, consistent reagents impacts reaction yields, purity, and process safety. Suppliers must demonstrate consistent product quality and adherence to stringent specifications.
Solvents and Excipients	While not direct synthetic components, high-purity solvents are critical for reaction media, extraction, and purification. Excipients, though used in the final drug product formulation, are sourced based on pharmaceutical-grade specifications and regulatory compliance.	Pharmaceutical-grade solvents ensure minimal contamination. Excipient suppliers are crucial for the final drug product's stability, bioavailability, and patient administration.

Identifying specific named suppliers for these raw materials is challenging due to the proprietary nature of pharmaceutical supply chains. However, established global chemical manufacturers with expertise in custom synthesis, fine chemicals, and pharmaceutical intermediates are likely candidates. These include companies operating in regions with strong chemical manufacturing infrastructure, such as China, India, Europe, and North America. Companies like Merck KGaA (Sigma-Aldrich), Thermo Fisher Scientific, BASF, Evonik Industries, and specialized API intermediate manufacturers often serve as suppliers in this segment.

Contract Manufacturing Organizations (CMOs) for Vimseltinib API and Drug Product

The manufacturing of vimseltinib, encompassing both the API and the final drug product, is likely managed through contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs). This outsourcing model allows pharmaceutical developers to leverage specialized expertise, infrastructure, and regulatory compliance without investing in extensive in-house manufacturing capabilities, particularly for niche or lower-volume drugs.

Table 2: CMO/CDMO Roles in Vimseltinib Production

Stage	Key Activities	Considerations for Partnering
API Manufacturing	- Process scale-up and optimization. - Commercial-scale synthesis of vimseltinib API. - Quality control and analytical testing. - Regulatory dossier support (CMC sections). - Supply chain management for raw materials.	- Proven track record in small molecule API synthesis and cGMP compliance. - Experience with complex organic synthesis and purification. - Robust quality management systems and regulatory inspection history. - Capacity to meet projected commercial demand. - Expertise in handling potent compounds (if applicable to vimseltinib).
Drug Product Formulation	- Development of stable and bioavailable dosage forms (e.g., capsules, tablets). - Excipient selection and sourcing. - Manufacturing of finished drug product. - Packaging and labeling. - Stability testing.	- Expertise in solid oral dosage forms. - Access to approved excipients. - cGMP compliance for drug product manufacturing. - Packaging capabilities that ensure product integrity and patient compliance. - Ability to handle serialization requirements.
Analytical Services	- Method development and validation for raw materials, in-process controls, and finished product. - Release testing. - Stability studies. - Impurity profiling.	- Accreditation (e.g., ISO 17025) and cGMP compliance. - Broad analytical capabilities. - Experienced scientific team. - Timely delivery of reliable data.
Regulatory Support	- Compilation of Chemistry, Manufacturing, and Controls (CMC) sections for regulatory submissions. - Support during regulatory inspections. - Change control management.	- Deep understanding of global regulatory requirements (FDA, EMA, etc.). - Experience in preparing and maintaining regulatory filings. - Proactive approach to regulatory compliance.

Given that vimseltinib (Turalio) is a recently approved drug, the developer, Daiichi Sankyo, likely has established relationships with specialized CDMOs for its production. Companies with a strong presence in oncology and orphan drug manufacturing, and with established regulatory track records, would be preferred partners. These may include:

• Lonza Group: A global leader in CDMO services with extensive experience in API and drug product manufacturing for complex molecules.
• Catalent: Offers integrated drug development and manufacturing solutions, including solid dose formulation and API manufacturing.
• Thermo Fisher Scientific (Patheon): Provides a broad range of development and manufacturing services across multiple modalities.
• WuXi AppTec: A significant player in API and drug product manufacturing, particularly with its strong base in Asia and global reach.
• Grand River (formerly PCI Pharma Services): Focuses on sterile fill-finish, but also offers drug product manufacturing and packaging.

The selection of a CDMO involves a rigorous qualification process to ensure alignment on technical capabilities, quality standards, regulatory compliance, and supply chain reliability.

Specialized Service Providers in the Vimseltinib Ecosystem

Beyond direct manufacturing, several specialized service providers are integral to the successful development, production, and commercialization of vimseltinib.

Table 3: Key Specialized Service Providers

Service Category	Description	Importance for Vimseltinib
Analytical Testing Laboratories	Independent laboratories that provide a wide range of analytical services, including raw material testing, in-process control, finished product release testing, stability studies, method development and validation, and impurity characterization.	Ensuring the quality, purity, and potency of vimseltinib at every stage of its lifecycle is non-negotiable. These labs provide critical data for regulatory submissions and ongoing quality assurance.
Regulatory Affairs Consultants	Experts who assist pharmaceutical companies in navigating the complex regulatory landscape for drug approval and post-approval compliance. This includes preparing and submitting regulatory dossiers (e.g., NDAs, MAAs), managing interactions with regulatory agencies, and ensuring adherence to cGMP, cGCP, and cGLP standards.	The approval of Turalio (vimseltinib) by the FDA in December 2023 signifies successful navigation of the regulatory pathway. Continued regulatory support is vital for market access, lifecycle management, and potential expansion into new indications or geographies.
Supply Chain and Logistics Providers	Companies specializing in the transportation, warehousing, and distribution of pharmaceutical products. This includes cold chain management (if required), serialization and track-and-trace solutions, and ensuring compliance with transportation regulations for hazardous materials.	Maintaining the integrity and traceability of vimseltinib from the manufacturing site to the patient is critical. Specialized logistics are needed to ensure product quality during transit and to meet the complex requirements of pharmaceutical distribution networks. Serialization helps combat counterfeiting.
Quality Assurance and Auditing Firms	External firms that conduct independent quality audits of suppliers, CMOs, and internal operations to ensure compliance with cGMP and other relevant quality standards. They provide an objective assessment of a company's quality management system.	Given the high stakes of pharmaceutical manufacturing, rigorous QA is paramount. Third-party auditors offer an independent perspective, identifying potential risks and areas for improvement in the supply chain and manufacturing processes. This is particularly important for ensuring ongoing compliance with regulatory expectations.
Intellectual Property Lawyers	Firms specializing in patent law, providing counsel on patent prosecution, freedom-to-operate analyses, patent litigation, and intellectual property strategy.	Protecting the intellectual property surrounding vimseltinib is foundational for its commercial success. IP lawyers ensure that manufacturing processes and supply chain partners do not infringe on existing patents and help secure patent protection for any new innovations related to vimseltinib.
Environmental Health & Safety (EHS) Consultants	Providers offering expertise in managing environmental impact, occupational health, and safety protocols within pharmaceutical manufacturing and chemical handling.	The synthesis of complex APIs often involves hazardous materials and processes. Ensuring strict adherence to EHS regulations is critical for worker safety, environmental protection, and regulatory compliance, preventing costly incidents and downtime.

These specialized service providers contribute to the overall robustness and compliance of the vimseltinib supply chain, enabling its reliable delivery to patients.

Regulatory Landscape and Compliance

The pharmaceutical industry operates under stringent regulatory oversight. For vimseltinib, compliance with Good Manufacturing Practices (GMP) is essential at all stages of production, from raw material sourcing to finished drug product release.

• FDA Approval: Vimseltinib (Turalio) received FDA approval on December 21, 2023 [1]. This approval signifies that the FDA has reviewed and accepted the drug's safety and efficacy data, as well as its manufacturing processes and controls.
• cGMP Compliance: All manufacturing facilities involved in producing vimseltinib API and drug product must adhere to current Good Manufacturing Practices (cGMP). This includes rigorous quality control, detailed record-keeping, process validation, and personnel training. Regulatory bodies like the FDA conduct inspections of these facilities to ensure compliance.
• ICH Guidelines: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are critical for global drug development and manufacturing. For vimseltinib, relevant ICH guidelines would include those on quality (e.g., Q7 for API GMP, Q8-Q11 for pharmaceutical development and quality risk management) and safety.
• Supply Chain Security: Pharmaceutical supply chains are increasingly subject to regulations aimed at ensuring product integrity and preventing counterfeiting. This includes serialization requirements, where each unit of the drug product is assigned a unique serial number for tracking and tracing throughout the supply chain.
• Environmental Regulations: Chemical manufacturing processes must comply with environmental regulations regarding emissions, waste disposal, and water usage.

Suppliers and CMOs involved in the vimseltinib supply chain are expected to have comprehensive quality management systems and a strong history of regulatory compliance. Audits by the drug developer and regulatory agencies are standard practice.

Key Takeaways

The supply chain for vimseltinib is multifaceted, involving specialized raw material providers, contract manufacturing organizations (CMOs/CDMOs), and a network of specialized service providers. The recent FDA approval of vimseltinib (Turalio) for TGCT underscores the importance of a reliable and compliant supply chain for this targeted therapy. Key considerations for stakeholders include:

• API Synthesis: Robust sourcing of advanced intermediates and chiral building blocks is critical, with established global chemical manufacturers and custom synthesis specialists being likely suppliers.
• CMO/CDMO Reliance: The manufacturing of both API and finished drug product is largely outsourced to CDMOs with proven expertise in small molecule synthesis, formulation, and cGMP compliance.
• Quality and Compliance: Strict adherence to cGMP, ICH guidelines, and other regulatory standards is non-negotiable, requiring robust quality management systems and a history of successful regulatory inspections.
• Specialized Services: Analytical testing, regulatory consulting, supply chain logistics, and IP protection are essential specialized services that underpin the successful commercialization of vimseltinib.
• Supply Chain Resilience: Diversification of suppliers and robust risk management strategies are crucial to mitigate potential disruptions and ensure continuous product availability for patients.

Frequently Asked Questions

1. What is the primary indication for vimseltinib? Vimseltinib is approved for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) that is unresectable or associated with severe morbidity.

2. Who is the developer of vimseltinib? Daiichi Sankyo is the developer of vimseltinib, which is marketed under the brand name Turalio.

3. What are the key regulatory requirements for vimseltinib suppliers? Suppliers must adhere to current Good Manufacturing Practices (cGMP), relevant International Council for Harmonisation (ICH) guidelines, and specific regulatory requirements of the markets where the drug will be sold.

4. Are there publicly listed direct suppliers for vimseltinib's active pharmaceutical ingredient (API)? Specific direct suppliers for proprietary APIs are typically confidential business relationships. However, companies manufacturing advanced intermediates and offering custom API synthesis are involved.

5. What is the role of contract manufacturing organizations (CMOs) in vimseltinib production? CMOs are responsible for the large-scale synthesis of the vimseltinib API and the formulation and manufacturing of the final drug product, including packaging and labeling.

---

Citations

[1] U.S. Food & Drug Administration. (2023, December 21). FDA approves first systemic therapy for tenosynovial giant cell tumor. U.S. Food & Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-systemic-therapy-tenosynovial-giant-cell-tumor